profit from every $100 of sales.
$0$100
PACS Group
$48.32+0.67% today
+234.9% in 1 year
1-year low $14.431-year high $50.26
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $40.04 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What PACS Group sold, what it kept, and what it did with the cash.
Sales went from $2.42 billion in 2022 to $5.29 billion in 2025, with $192 million of profit last year.
SalesProfit
PACS Group vs. similar companies
PACS Group grows in the middle of these 5 and is the most expensive for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| PACS Group | 40.0× · Expensive | ||
 HCA Healthcare | 15.4× · Fair price | ||
 Fresenius SE & Co. KGaA | 23.9× · Fair price | ||
 IHH Healthcare Berhad | 34.3× · Expensive | ||
 Rede D'Or São Luiz | 16.2× · Fair price |
Compare PACS Group with The Ensign Group · National HealthCare
AI analysis
An AI analyst reads PACS Group's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 2,422 | 3,111 | 4,090 | 5,289 | |
| 401 | 447 | 508 | 780 | |
| 229 | 208 | 123 | 310 | |
| 255 | 233 | 187 | 368 | |
| 150 | 113 | 56 | 192 | |
| 1.00 | 0.76 | 0.38 | 1.22 | |
| 16.5% | 14.4% | 12.4% | 14.8% | |
| 9.5% | 6.7% | 3.0% | 5.9% | |
| 6.2% | 3.6% | 1.4% | 3.6% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 2,462 | 3,513 | 5,243 | 5,584 |
| Cash | 58 | 73 | 158 | 197 |
| Total debt | 1,926 | 2,805 | 3,501 | 3,471 |
| Total liabilities | 2,393 | 3,411 | 4,527 | 4,632 |
| 64 | 96 | 710 | 947 | |
| 150 | 148 | 149 | 157 | |
| 9.2% | 5.6% | 2.7% | 5.6% | |
| 236.5% | 117.4% | 7.9% | 20.2% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 93 | 64 | 367 | 404 | |
| 78 | 173 | 350 | 249 | |
| 14 | -109 | 18 | 155 | |
| Dividends paid | 60 | 80 | 34 | 0 |
| – | – | – | – | |
| 0 | 0 | 116 | 54 |
Valuation
- 40.0×
- 23.3×
- 5.91
- 8.3×
- 1.5×
- 49.5×
- 29.7×
- 2.0%
- 2.5%
- 0.0%
Profitability
- 14.8%
- 5.9%
- 3.6%
- 8.2%
- 5.7%
- 5.9%
- 26.6%
- 4.3%
- 8.3%
- –
Growth
- +29.7%
- +6.8%
- −0.7%
- –
- +1.4%
Financial health
- 8.9×
- 3.67
- 54.7%
- 11.0×
- 1.07
- 0.99
- 0.96
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 49%of 952
Bottom 39%of 884
Bottom 30%of 601
Top 18%of 886
Top 43%of 987
What analysts expect
- Average price target
- $44.67
- Range
- $40.00 – $52.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 11, 2026 | 0.50 | 0.42 | +19.0% |
| Feb 26, 2026 | 0.43 | 0.48 | −10.4% |
| Nov 19, 2025 | 0.32 | 0.45 | −28.9% |
| Aug 12, 2024 | -0.07 | 0.35 | −120.7% |
| May 13, 2024 | 0.33 | 0.29 | +13.7% |
| Sep 30, 2023 | 0.13 | – | – |
| Jun 30, 2023 | 0.14 | – | – |
| Mar 31, 2023 | 0.25 | – | – |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
26No pass
Benjamin Graham
19No pass
Philip Fisher
29No pass
Peter Lynch
25No pass
Joel Greenblatt
4No pass
Charlie Munger
19No pass
Terry Smith
25No pass
Questions about PACS Group
Is PACS Group a good stock to buy?
A business with weak numbers, but the price is high. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the PACS Group AI analysis
What does PACS Group do?
PACS Group, Inc., through its subsidiaries, operates skilled nursing facilities and assisted living facilities in the United States. It also provides senior care and independent living facilities. It is in Medical Care Facilities, based in Salt Lake City, UT, United States, with 47,455 employees.
Does PACS Group pay a dividend?
No. PACS Group does not pay a dividend at the moment.
Is PACS Group stock halal?
No. PACS Group does not pass our halal screen: its debt is 45% of its market value, at or above the 33% limit. How we check
How has PACS Group stock done over the past year?
Up 234.9% over the past twelve months, to $48.32. It traded between $14.43 and $50.26 and is 3.9% below its high.
Who are PACS Group's competitors?
The largest listed companies in the same industry are HCA Healthcare, Fresenius SE & Co. KGaA, IHH Healthcare Berhad and Rede D'Or São Luiz. The peers table on this page compares their profit, growth and price with PACS Group's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.